Spyre Therapeutics (SYRE) Stifel 2024 Immunology and Inflammation Virtual Summit summary

Market landscape and unmet needs

• Inflammatory bowel disease (IBD) affects 2.4 million Americans, with significant unmet therapeutic needs due to limited remission rates and suboptimal dosing regimens.

• Current therapies, such as Entyvio, are favored for their safety but require frequent dosing and do not surpass a 25% placebo-adjusted remission ceiling.

• The market is highly competitive, valued at over $20 billion, with new agents entering but struggling to improve efficacy without added safety risks.

• Combination therapies, as shown in J&J's VEGA study, have demonstrated the potential to nearly double remission rates without increasing safety concerns.

Pipeline strategy and innovation

• Focus is on developing extended half-life antibodies targeting key IBD pathways, aiming for dosing intervals of every 8 to 12 weeks, improving patient convenience.

• SPY001 is designed to match Entyvio's potency and selectivity but incorporates a YTE modification to triple its half-life, enabling less frequent dosing.

• High-concentration subcutaneous formulations and increased dosing are expected to further extend dosing intervals.

• Phase I data for SPY001, expected by year-end, will determine if quarterly dosing is achievable.

Clinical development and timelines

• Phase I studies for SPY001 and two TL1A molecules are underway, with data readouts anticipated by the end of the year and first half of next year, respectively.

• Phase II studies will incorporate both monotherapies and combinations, with design details to be announced in the first half of next year.

• The company is positioned to deliver multiple clinical catalysts and launch phase II studies with current cash reserves.